Tye-Din, Jason A.
,
Daveson, A. James M.
Goldstein, Kaela E.
Hand, Holly L.
Neff, Kristin M.
Goel, Gautam
Williams, Leslie J.
Truitt, Kenneth E.
Anderson, Robert P.
Funding for this research was provided by:
ImmusanT, Inc.
Article History
Received: 23 August 2020
Accepted: 27 October 2020
First Online: 26 November 2020
Ethics approval and consent to participate
: The study was conducted in accordance with the International Conference on Harmonisation for Good Clinical Practice. Local ethics committees approved the study (AUS: Melbourne Health Human Research Ethics Committee, Parkville VIC; Bellberry Limited, Eastwood SA; Uniting Care Health, Eastwood SA; NZ: Central Health and Disability Ethics Committee, Thorndon, Wellington; US: Copernicus Group IRB, Cary NC; Columbia University IRB, New York NY; Mayo Clinic IRB, Rochester MN and The University of Chicago IRB, Chicago IL) See Additional fileInternalRef removed: Table S9 for additional details. Written, informed consent was obtained from each patient included in the study.
: Not applicable
: GG, KEG, HLH, KMN, KET, LJW and RPA were former employees of ImmusanT, Inc. JAT-D and AJMD served as advisors to ImmusanT, Inc. RPA is the inventor of patents, owned or licenced by ImmusanT, Inc., relating to the diagnostic application of gluten challenge.